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Influence of dialysis membranes on outcomes in acute renal Many variables may affect the outcome of patients
failure: A meta-analysis. undergoing dialysis for acute renal failure (ARF) such
Background. Considerable controversy exists as to whether as the delivered dose of dialysis [1, 2], the timing ofsynthetic (more biocompatible) dialysis membranes improve
initiation of dialysis [2, 3], nature of dialyzer membranesoutcome in patients with acute renal failure (ARF) compared
[4–6], the severity of the underlying illnesses, and theto cellulose-based membranes. Numerous trials conducted
have yielded inconsistent results. Although the discordant re- effects of co-morbidity and the response to co-interven-
sults of existing studies could be explained by the varying tions [7]. It has been demonstrated that activation of
degrees of biocompatibility among the different membranes
complement and coagulation factors occurs during con-used, these studies also had low statistical power. Thus, we
tact between blood and the dialysis membrane [8, 9].sought to determine whether combining results from all pub-
lished trials would provide a better estimate of the effect of Neutrophil activation and sequestration occurs in the
membrane composition on survival in ARF. lungs and other organs as well. All these factors contrib-
Methods. We performed a meta-analysis of all previously ute to the hemodynamic changes and hypersensitivity-published prospective trials comparing the use of synthetic
like reactions during dialysis. This is especially apparentmembranes with cellulose-based membranes for hemodialysis
with cellulose-based membranes that activate the alter-in patients with ARF.
Results. Of the 10 prospective trials identified, eight trials native pathway of complement, both in vitro and in vivo
(867 patients) provided survival data and six trials (641 pa- [10]. Cellulose membranes can be broadly classified into
tients) provided data on recovery of renal function. We used
unsubstituted (also called cuprophane) membranes andthe Mantel-Haenszel test based on a fixed effects model to
substituted membranes such as cellulose acetate and cel-analyze the data. The cumulative odds ratio (OR) for survival
in favor of synthetic membranes was 1.37 (95% CI: 1.02 to lulose diacetate. Cuprophane is a polysaccharide-based
1.83), P  0.03 and that for renal recovery was 1.23 (95% CI: membrane obtained from pressed cotton. It is composed
0.90 to 1.68), P  0.18. We performed a sensitivity analysis by of chains of glucosan rings with abundant free hydroxylstratifying studies on the basis of control group membrane
groups. Substituted cellulose membranes are obtainedtype (unsubstituted or substituted cellulose) and found that
by chemical bonding of a material to the free hydroxylthe survival advantage for synthetic membranes was mainly
limited to comparison with the unsubstituted cellulose group groups at the surface of the cellulose polymer. The most
[OR 1.64 (95% CI: 1.10 to 2.45) vs. OR 1.20 (95% CI: 0.73 to common type of substituted cellulose is cellulose acetate,
1.97)].
in which acetate replaces 80% of the hydroxyl groups.Conclusions. Synthetic membranes appear to confer a sig-
Cellulosynthetic membranes are modified by the addi-nificant survival advantage over cellulose-based membranes.
We could not demonstrate a similar benefit with use of syn- tion of a synthetic material (such as diethylaminoethyl
thetic membranes over cellulose-based membranes for recov- in the production of hemophan) to liquefied cellulose
ery of renal function but sample size was limited. Finally, our during its formation. Often, these membranes are looselyresults suggest that the survival disadvantage for cellulose-
defined as “non-biocompatible” membranes, althoughbased membranes may be limited to unsubstituted cellulose
the term is imprecise. The performance of these mem-(cuprophane) membranes.
branes is determined additionally by a number of factors,
including the sieving characteristics, ultrafiltration coef-Key words: acute renal failure, biocompatible membranes, dialysis,
synthetic membranes, cellulose. ficient, and adsorption characteristics. The newer syn-
thetic membranes, such as polyacrylo nitrile (PAN), po-
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have been again loosely dubbed as “biocompatible” RESULTS
membranes [11, 12], although these membranes tend to We identified 10 prospective trials that had analyzed
vary in their degree of biocompatibility as well. Many the effect of synthetic versus cellulose-based membranes
studies have assessed the effect of biocompatibility on on the outcomes in patients undergoing dialysis for ARF,
outcomes in patients undergoing dialysis for ARF and seven of which were published as full reports [4–6, 13–16]
have reported inconsistent results. However, no single and three as abstracts (Mehta R, J Am Soc Nephrol.
study has been of sufficient size to be definitive. Thus, 7:1457A, 1996; Albright RC, J Am Soc Nephrol 9:197A,
we undertook a meta-analysis of these studies in an effort 1998; Assouad M, J Am Soc Nephrol 7:1437A, 1996).
to better delineate the effects of dialysis membrane com- From these studies we excluded the abstract by Mehta
position on survival and recovery of renal function in et al because it did not report actual survival rates and
patients with ARF. because it was a trial designed primarily to study out-
come differences between continuous and intermittent
dialysis. We also excluded the trial by Hakim, Wingard,METHODS
and Parker [13] because the data from this trial were
Identification of trials
included in the subsequent publication by Himmelfarb
We identified published trials by Medline search from et al [14]. We analyzed recovery of renal function data
January 1966 to December 2000 using the following key in the six trials [4, 6, 14, 16] and abstracts (Albright RC,
words: dialysis, biocompatible membranes, and acute re- J Am Soc Nephrol 9:197A, 1998; and Assouad M, J Am
nal failure. Both English and non-English language jour- Soc Nephrol 7:1437A, 1996) in which it was available.
nals were searched. We also tried to identify any addi- We included the abstracts for our analysis because these
tional unpublished trials and abstracts by reviewing our reports included high-quality trials with negative results,
files, consisting of personal correspondence, proceedings such that their exclusion could have produced an overes-
from meetings, and bibliographies of review articles. timation of any treatment effect.
Each author independently reviewed each article. We Four trials suggested a possible survival benefit for
abstracted data in a non-blinded fashion as no qualitative patients dialyzed with synthetic membranes and four
appraisal was performed. trials did not (Table 1). Overall survival (N  867) was
Studies were required to meet the following inclusion 62% with synthetic and 55% with cellulose-based mem-
criteria: (1) the study must have been a prospective trial; branes [OR 1.37 (95% CI: 1.02 to 1.83), P  0.03] (Fig.
(2) the study must have compared cellulose-based mem- 1). Overall renal recovery (N  641) was 53% for syn-
branes with synthetic membranes; (3) the study must thetic and 50% for cellulose-based membranes [OR 1.23
have included assessment of survival and/or recovery of (95% CI: 0.90 to 1.68), P  0.18].
renal function; and (4) the study must have been pub- The results of our sensitivity analysis are shown in
lished in some form (abstracts were included). Figure 2. We found a significant survival benefit with
use of synthetic membranes over cuprophane [OR 1.64
Outcome measures
(95% CI: 1.10 to 2.45), P  0.013] but not over cellulose
We studied the following outcomes: (1) all-cause mor- acetate [OR 1.20 (95% CI: 0.73 to1.97). Similar analysis
tality at the end of the follow-up period; and (2) recovery of renal recovery data showed no significant benefit with
of renal function defined as the discontinuation of dial- use of synthetic membranes over cuprophane [OR 1.38
ysis because it was no longer required. (95% CI: 0.80 to 2.37)] or over cellulose acetate [OR
1.16 (95% CI: 0.72 to 1.86)].
Statistical analysis
Analysis of the two published studies using well-
Data were analyzed based on a fixed effects model defined randomization methods [4, 16] and two abstracts
using the Mantel-Haenszel test to estimate heterogeneity (Albright RC, J Am Soc Nephrol 9:197A, 1998; and As-
between studies. We calculated a cumulative odds ratio souad M, J Am Soc Nephrol 7:1437A, 1996) demon-
(OR) for survival and renal recovery using the weights strated no survival benefit for synthetic membranes [OR
from the Mantel-Haenszel test. 1.15 (95% CI: 0.74 to 1.80)] (Fig. 2). Analysis of recovery
Due to considerable variation in study characteristics, data for these trials again showed no benefit for synthetic
especially with regard to the nature of membrane used membranes [OR 0.95 (95% CI: 0.61-1.46)].
and the study design, we performed a sensitivity analysis
by stratifying for these two variables. Trials that used
DISCUSSIONcellulose acetate and those that used cuprophane were
analyzed independently. Further stratification was done The primary result of our meta-analysis is that dialysis
membrane composition influences all-cause mortality inbased on methodological issues. We identified studies
that had well-defined randomization methods and re- ARF. While statistical power limited our ability to distin-
guish between various types of membranes, our findingspeated our analyses using only these studies.
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Table 1. Summary of results of clinical trials assessing the impact of membrane on outcomes in patients with acute renal failure
No. of Membranes Follow-up OR for survival OR for renal
Trial patients Design compared period (95% CI) recovery (95% CI)
Schiffl et al 52 Prospective Cuprophane 3 months 3.022 (0.99 to 9.21) 3.88 (1.17 to 12.84)
RCT vs. PAN
Jorres et al 160 Prospective Cuprophane 14 days after end 1.06 (0.57 to 2.00) 1.02 (0.54 to 1.91)
RCT vs. PMMA of HD
Himmelfarb et al 153 Prospective Cellulose acetate 3 to 4 years 1.57 (0.83 to 2.97) 2.32 (1.21 to 4.46)
CT vs. PMMA/PS
Kurtal, von Herrath, 57 Prospective Cuprophane vs. 4 weeks 0.69 (0.23 to 2.09) Not reported
and Schaeffer CT polyamide
Gastaldello et al 159 Prospective Cellulose diacetate 80 days 0.82 (0.33 to 2.02) 0.47 (0.17 to 1.27)
RCT vs. PS
Neveu et al 169 Prospective Cuprophane vs. 6 months 3.14 (1.50 to 6.56) Not reported
PAN/PS/polyamide
Albright (abstract) 66 Prospective Cellulose acetate 30 days 0.85 (0.28 to 2.51) 1.16 (0.60 to 2.25)
RCT vs. polysulfone
Assouad (abstract) 51 Prospective Cellulose acetate vs. Unclear 0.76 (0.25 to 2.33) 0.48 (0.16 to 1.49)
RCT PMMA
All studies 867a 1.37 (1.02 to 1.83)b 1.23 (0.90 to 1.68)b
combined P  0.03 P  0.18
Abbreviations are: RCT, randomized controlled trial; CT, controlled trial; PMMA, polymethyl methyl acrylate; PAN, poly acrylo nitrile.
aRenal recovery data was reported in only 641 patients
bMantel-Haenszel test combined odds ratio
Fig. 1. Forrest plot for survival. Odds ratios
() with corresponding 95% CI (lines) from
individual trials for survival in patients under-
going hemodialysis for acute renal failure
(ARF) using synthetic vs. cellulose-based
membranes. *Abstracts.
suggest a significant overall survival benefit with the use used, the duration of follow-up period, the nature of
patients enrolled, the study design, and the dosage ofof synthetic membranes over cellulose-based membranes
for dialysis in ARF. As with any meta-analysis, there dialysis. We therefore performed a sensitivity analysis
by stratification for the kind of membrane used and themay be a significant impact of study homogeneity and
methodological quality on the final result [17]. Although study design in order to assess the impact of these differ-
ences. Although it would have been desirable to extendthe results of the Mantel-Haenszel test found homogene-
ity among the results of the trials, it is apparent that the the sensitivity analysis to the other variables mentioned
above, the lack of data in the primary trials does notstudies differed in many methodological aspects. Most
important, studies differed in the nature of membranes permit us to do so. Clearly, not all the studies used the
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of synthetic membrane, but some trials used more than
one kind of membrane thus precluding this secondary
analysis.
With regard to study design, we found that not all the
trials were as methodologically strict, particularly with
regard to randomization procedures. The trials by Him-
melfarb et al [14] and Kurtal, von Herrath, and Schaefer
[15] assigned patients in alternating order and thus allo-
cation concealment was not achieved. The study by
Neveu et al [5] was a nonrandomized trial. The study by
Schiffl et al [4] was terminated early at 52 patients, even
though the intent was to enroll 106 patients and there
might have been an unequal distribution of septic pa-
tients between the two study groups. Furthermore, the
authors in this study did not provide information on theFig. 2. Sensitivity analysis (survival) Forrest plot showing survival data
nature of the septic process or the number of septicfor the different groups used in the sensitivity analysis. *Odds ratio for
survival using synthetic membrane. Four studies were included in each patients at baseline in each study group. We therefore
group. In the synthetic vs. cellulose-acetate group, the studies by Him- stratified the studies further by excluding these trials.melfarb et al [14], and Gastaldello et al [6], plus the abstracts by Albright
The result of our sensitivity analysis, after stratifying forand Assouad were included. The synthetic vs. cuprophane group in-
cluded studies by Schiffl et al [4], Jorres et al [16], Kurtal, von Herrath, methodology, suggests that there is no significant survival
and Schaefer [15], and Neveu et al [5]. The randomized control trials benefit with the use of synthetic membranes. However,(RCTs) only group included both studies using cellulose-acetate and
again, the direction of effect is the same and statisticalthose using cuprophane. These studies included Schiffl et al [14] and
Jorres et al [16] and the abstracts by Albright and Assouad. We excluded power is reduced by this subgroup analysis. These results
studies from this latter group for failure of assignment concealment and/or do suggest that the true effect size of synthetic mem-studies with unequal distribution of baseline patient characteristics.
branes may be smaller than estimated by less rigorous
study designs, a result in keeping with the meta-analysis
literature [17].
same set of synthetic/cellulose-based membranes. We Publication bias is yet another factor to be considered
found in our sensitivity analysis that synthetic mem- when reporting meta-analysis since negative trials are
branes appear to confer a survival advantage over cupro- sometimes less likely to be published. Therefore, we
phane but not over cellulose acetate membranes. How- made every effort to include both positive and negative
ever, statistical power was limited and the same direction trials to minimize this effect. Finally, although the results
of effect is seen in both membrane types. In other words, of our meta-analysis do not show a statistically significant
synthetic membranes were never found to be inferior to benefit for the recovery of renal function with use of
cellulose-based membranes. Indeed, results of studies synthetic membranes, the wide variation in the follow-
examining the effects of membrane materials on leuko- up period and the insufficient statistical power of the
cytes in vitro are consistent with our findings in that trials that analyzed renal recovery do make it difficult
cellulose-based membranes performed worst and syn- to draw a definitive conclusion regarding this end point.
thetic membranes best [18]. Our inability to demonstrate
a statistical difference between synthetic and cellulose
CONCLUSIONacetate membranes in terms of survival, or between any
In summary, our results suggest that synthetic mem-membrane in terms of renal recovery, may have been a
branes are associated with improved survival comparedfunction of limited statistical power. Finally, although
to cellulose-based membranes in patients undergoing di-both cuprophane and cellulose acetate membranes are
alysis for ARF. It is unclear whether this survival advan-traditionally classified as “non-biocompatible” and “cel-
tage extends to partially synthetic membranes like cellu-lulose-based,” they vary in their degree of incompatibility
lose acetate/diacetate. The results of our sensitivity analysisdue to their composition, specifically the substitution of
suggest that the disadvantages of cuprophane membranesthe hydroxyl groups by acetate. Furthermore, the amount
may not extend to these substituted cellulose membranesof acetate present in cellulose acetate membranes influ-
(cellulose acetate). However, this subgroup analysis is alsoences biocompatibility such that highly substituted mem-
limited by statistical power. This issue could be clarifiedbranes (i.e., tri-acetate) may be more compatible. In
in the future by larger, methodologically robust trialsaddition, different kinds of synthetic membranes also
vary in their compatibility characteristics and this could designed specifically to compare cellulose acetate mem-
branes with synthetic membranes. However, it is unlikelyhave a significant impact on our results. Therefore, we
considered trying to stratify the trials based on the nature that such trials will be undertaken given the small differ-
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